Zobrazeno 1 - 10
of 245
pro vyhledávání: '"Rawstron AC"'
Publikováno v:
Oncogenesis, Vol 8, Iss 5, Pp 1-11 (2019)
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries. It has recently been shown that the homogeneity of the chromatin landscape between CLL cells contrasts with the important observed genetic heterogeneity of the dis
Autor:
Oughton, JB, Collett, L, Howard, DR, Hockaday, A, Munir, T, McMahon, K, McParland, L, Dimbleby, C, Phillips, D, Rawstron, AC, Hillmen, P
Publikováno v:
Trials, Vol 18, Iss 1, Pp 1-12 (2017)
Trials
Oughton, JB, Collett, L, Howard, D R, Hockaday, A, Munir, T, McMahon, K, McParland, L, Dimbleby, C, Phillips, D, Rawstron, A C & Hillmen, P 2017, ' GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial : study protocol for a phase II/III randomised controlled trial. ', Trials, vol. 18, 353 . https://doi.org/10.1186/s13063-017-2107-0
Trials
Oughton, JB, Collett, L, Howard, D R, Hockaday, A, Munir, T, McMahon, K, McParland, L, Dimbleby, C, Phillips, D, Rawstron, A C & Hillmen, P 2017, ' GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial : study protocol for a phase II/III randomised controlled trial. ', Trials, vol. 18, 353 . https://doi.org/10.1186/s13063-017-2107-0
Background Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and regardless
Autor:
Rawstron, AC, Kreuzer, K-A, Soosapilla, A, Spacek, M, Stehlikova, O, Gambell, P, McIver-Brown, N, Villamor, N, Psarra, K, Arroz, M, Milani, R, de la Serna, J, Cedena, MT, Jaksic, O, Nomdedeu, J, Moreno, C, Rigolin, GM, Cuneo, A, Johansen, P, Johnsen, HE, Rosenquist, R, Niemann, CU, Kern, W, Westerman, D, Trneny, M, Mulligan, S, Doubek, M, Pospisilova, S, Hillmen, P, Oscier, D, Hallek, M, Ghia, P, Montserrat, E
Publikováno v:
Rawstron, A C, Kreuzer, K, Soosapilla, A, Spacek, M, Stehlikova, O, Gambell, P, Mciver-brown, N, Villamor, N, Psarra, K, Arroz, M, Milani, R, De La Serna, J, Cedena, M T, Jaksic, O, Nomdedeu, J, Moreno, C, Rigolin, G M, Cuneo, A, Johansen, P, Johnsen, H E, Rosenquist, R, Niemann, C U, Kern, W, Westerman, D, Trneny, M, Mulligan, S, Doubek, M, Pospisilova, S, Hillmen, P, Oscier, D, Hallek, M, Ghia, P & Montserrat, E 2018, ' Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry : An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project ', Cytometry. Part B: Clinical Cytometry, vol. 94, no. 1, pp. 121-128 . https://doi.org/10.1002/cyto.b.21595
Rawstron, A C, Kreuzer, K-A, Soosapilla, A, Spacek, M, Stehlikova, O, Gambell, P, McIver-Brown, N, Villamor, N, Psarra, K, Arroz, M, Milani, R, de la Serna, J, Cedena, M T, Jaksic, O, Nomdedeu, J, Moreno, C, Rigolin, G M, Cuneo, A, Johansen, P, Johnsen, H E, Rosenquist, R, Niemann, C U, Kern, W, Westerman, D, Trneny, M, Mulligan, S, Doubek, M, Pospisilova, S, Hillmen, P, Oscier, D, Hallek, M, Ghia, P & Montserrat, E 2018, ' Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry : An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project ', Cytometry. Part B: Clinical Cytometry, vol. 94, no. 1, pp. 121-128 . https://doi.org/10.1002/cyto.b.21595
Cytometry. Part B, Clinical Cytometry
CYTOMETRY PART B-CLINICAL CYTOMETRY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Rawstron, A C, Kreuzer, K-A, Soosapilla, A, Spacek, M, Stehlikova, O, Gambell, P, McIver-Brown, N, Villamor, N, Psarra, K, Arroz, M, Milani, R, de la Serna, J, Cedena, M T, Jaksic, O, Nomdedeu, J, Moreno, C, Rigolin, G M, Cuneo, A, Johansen, P, Johnsen, H E, Rosenquist, R, Niemann, C U, Kern, W, Westerman, D, Trneny, M, Mulligan, S, Doubek, M, Pospisilova, S, Hillmen, P, Oscier, D, Hallek, M, Ghia, P & Montserrat, E 2018, ' Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry : An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project ', Cytometry. Part B: Clinical Cytometry, vol. 94, no. 1, pp. 121-128 . https://doi.org/10.1002/cyto.b.21595
Cytometry. Part B, Clinical Cytometry
CYTOMETRY PART B-CLINICAL CYTOMETRY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::df5bb5f57d8305a42d707dab013dbc73
https://curis.ku.dk/ws/files/228312240/cyto.b.21595_10.1002_ISSN_1552_4957.2018iccs_virutal_collection.pdf
https://curis.ku.dk/ws/files/228312240/cyto.b.21595_10.1002_ISSN_1552_4957.2018iccs_virutal_collection.pdf
Autor:
Rawstron, AC, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, RM, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, AP, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, JL, Stetler-Stevenson, M, Yuan, C, Broome, HE, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, CM, Emerson, R, Robins, HS, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, TJ, Wierda, WG, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P, CLL, ERIC European Res Initiative
Publikováno v:
Leukemia
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Leukemia, vol 30, iss 4
Leukemia, 30(4), 929-936. Nature Publishing Group
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223b87a88cadbba63e43e546bd4fa680
Autor:
Collett, L, Howard, DR, Munir, T, McParland, L, Oughton, JB, Rawstron, AC, Hockaday, A, Dimbleby, C, Phillips, D, McMahon, K, Hulme, C, Allsup, D, Bloor, A, Hillmen, P
Background Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. How
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::6d3cb8476e36d522f4e9ee5009572824
Autor:
Varghese, A, Howard, DR, Pocock, C, Rawstron, AC, Follows, G, McCarthy, H, Dearden, C, Fegan, C, Milligan, D, Smith, AF, Gregory, WM, Hillmen, P
With immunochemotherapy, remission duration and survival in patients with CLL is dependent on the level of minimal residual disease after treatment. This phase II trial assessed alemtuzumab consolidation post-chemotherapy in patients who responded wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::08e25f9fa1239fcd9e742e9f53855d81
Autor:
Kwok, M, Rawstron, AC, Varghese, A, Evans, PAS, O'Connor, SJM, Doughty, C, Newton, DJ, Moreton, P, Hillmen, P
Minimal residual disease (MRD) negativity, defined as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::3fe8159b88c0be281fffe8c2bcaf5506
Autor:
Rawstron, Ac, Kreuzer, Ka, Soosapilla, A, Spacek, M, Gambell, P, McIver brown, N, Psarra, K, Arroz, M, Milani, R, de la Serna, J, Cedena, Mt, Jaksic, O, Nomdedeu, Jf, Moreno, C, Rigolin, Gian Matteo, Cuneo, Antonio, Johansen, P, Johnsen, He, Rosenquist, R, Niemann, Cu, Kern, W, Westerman, Da, Trneny, M, Mulligan, Sp, Hillmen, P, Oscier, Dg, Hallek, M, Ghia, P, Montserrat, E.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3709::9317228925052722215216e6964e200f
http://hdl.handle.net/11392/2363355
http://hdl.handle.net/11392/2363355
Autor:
Bottcher, S, Rawstron, AC, Lucio, P, Macintyre, E, Lima, M, van der Velden, Vincent, Dongen, Jacques, Orfao, A, Kneba, M, van Dongen, JJM, Dik, WA, Langerak, AW, van der Velden, VHJ, Hooijkaas, H
Publikováno v:
Nieuwe ontwikkelingen in de Medische Immunologie 2010, 355-371
STARTPAGE=355;ENDPAGE=371;TITLE=Nieuwe ontwikkelingen in de Medische Immunologie 2010
STARTPAGE=355;ENDPAGE=371;TITLE=Nieuwe ontwikkelingen in de Medische Immunologie 2010
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::662180245a5f59c7fda047b2ddc3cba1
https://pure.eur.nl/en/publications/75eb0883-f8f0-4f93-9dbc-1d080dd476c7
https://pure.eur.nl/en/publications/75eb0883-f8f0-4f93-9dbc-1d080dd476c7